Who founded Aro Biotherapeutics?

Aro Biotherapeutics was founded by Karyn O'Neil, Susan Dillon in 2017.

Who are Aro Biotherapeutics's investors?

Aro Biotherapeutics's investors include Avego BioScience Capital, HealthCap, Agent Capital, Biotechnology Value Fund, Cowen Healthcare Investments, Johnson & Johnson Innovation – JJDC, Northpond Ventures.

How much funding has Aro Biotherapeutics raised?

Aro Biotherapeutics has disclosed $164.4M raised across 5 of its 6 known rounds.

Where is Aro Biotherapeutics headquartered?

Aro Biotherapeutics is headquartered in Philadelphia, US.

Aro Biotherapeutics

Philadelphia, US · Founded 2017 · Delaware corporation · 7 known investors

Find your way into Aro Biotherapeutics

Each arrow is one introduction. Sign up to fill in the first one.

61 people can intro you to Susan

Ask Steve Liapis to introduce you to Susan Dillon

You →Steve · together at Aro Biotherapeutics →Susan

Your email: who you already know at Aro Biotherapeutics, and who your contacts know
2nd- and 3rd-degree connections: people you know who worked, studied or invested with the Aro Biotherapeutics team
Your LinkedIn: the connections who can make the intro for you

We rank every route by how warm it is, so you raise on warm intros instead of cold emails.

Aro Biotherapeutics develops tissue-targeted genetic medicines using a proprietary protein technology called Centyrins. The company builds a wholly-owned pipeline of Centyrin-based therapeutic candidates and partners with industry to enable tissue-specific targeting of therapeutics across a range of diseases.

Biotech Healthtech

Founders & leadership

Aro Biotherapeutics was founded in 2017 by Karyn O'Neil and Susan Dillon.

Karyn O'NeilCo-founder

Susan Dillon Co-founder · Board ChairSusan Dillon earned a Ph.D. in Microbiology and Immunology from Thomas Jefferson University and completed a postdoctoral fellowship in Immunology at Duke University. She held multiple leadership roles at Centocor and Janssen Research & Development from 2001 to 2017, including Global Therapeutic Area Head for immunology, overseeing discovery and development of immunology therapeutics, before co-founding Aro Biotherapeutics.

Mark V. LaurenziNamed on SEC filing

Board

Elizabeth AndersonBoard director

Bruce PeacockBoard directorOperating Partner at Agent Capital

Investors · 7

Funding

SEC filings, press & company announcements

$164.4M disclosed across 5 of 6 rounds · 2018–2023

$41.5MSeries BNov 2023 · 2 sources
Cowen Healthcare Investments (lead), BVF Partners, Healthcap, Johnson & Johnson Innovation – JJDC, Northpond Ventures
Source ↗

▶$24MraisedDec 2022 · 12 investors · Pharmaceuticals

Rule 506(b)

Officers, directors & promoters on the filing

Christopher MirabelliDirector
Susan B DillonExecutive Officer, Director
Scott GreenbergExecutive Officer
Karyn O'NeilExecutive Officer, Director
Marten SteenDirector
Bruce PeacockDirector
Elizabeth AndersonDirector
Daniel JanseDirector
Mark LaurenziExecutive Officer
Kevin RaidyDirector
Mittie DoyleExecutive Officer

Offering amount: $100M
Amount sold: $24M
First sale: Dec 2022
Incorporated: Corporation, Delaware, 2017
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

▶$90.3MraisedDec 2021 · 14 investors · Pharmaceuticals

Rule 506(b)

Officers, directors & promoters on the filing

Scott GreenbergExecutive Officer
Jess LiftonDirector
Marten SteenDirector
Kevin RaidyDirector
Christopher MirabelliDirector
Daniel JanseDirector
Elizabeth AndersonDirector
Mark LaurenziExecutive Officer
Karyn O'NeilExecutive Officer, Director
Susan B DillonExecutive Officer, Director
Bruce PeacockDirector

Offering amount: $90.3M
Amount sold: $90.3M
First sale: Dec 2020
Incorporated: Corporation, Delaware, 2017
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

▶$5MraisedJan 2020 · 1 investors · Biotechnology

Rule 506(b)

Officers, directors & promoters on the filing

Bruce PeacockDirector
Mark LaurenziExecutive Officer
Karyn O'NeilExecutive Officer, Director
Susan B DillonExecutive Officer, Director
Elizabeth AndersonDirector

Offering amount: $5M
Amount sold: $5M
First sale: Dec 2019
Incorporated: Corporation, Delaware, 2017
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

▶$3.5MraisedApr 2019 · 3 investors · Biotechnology

Rule 506(b)

Officers, directors & promoters on the filing

Susan B DillonExecutive Officer, Director
Karyn O'NeilExecutive Officer, Director
Mark V. LaurenziExecutive Officer
Elizabeth AndersonDirector
Bruce PeacockDirector

Offering amount: $4.9M
Amount sold: $3.5M
First sale: Mar 2019
Incorporated: Corporation, Delaware, 2017
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

In the news

Aro Biotherapeutics Raises $41.5M Series B Financingfinsmes.com · Nov 2023

Aro Biotherapeutics Raises $13 Million and Establishes Leadership Team to Develop Next Generation of Protein Therapeutics - BioSpacebiospace.com · Dec 2018

Frequently asked questions

What does Aro Biotherapeutics do?: Aro Biotherapeutics develops tissue-targeted genetic medicines using a proprietary protein technology called Centyrins. The company builds a wholly-owned pipeline of Centyrin-based therapeutic candidates and partners with industry to enable tissue-specific targeting of therapeutics across a range of diseases.
Who founded Aro Biotherapeutics?: Aro Biotherapeutics was founded by Karyn O'Neil, Susan Dillon in 2017.
Who are Aro Biotherapeutics's investors?: Aro Biotherapeutics's investors include Avego BioScience Capital, HealthCap, Agent Capital, Biotechnology Value Fund, Cowen Healthcare Investments, Johnson & Johnson Innovation – JJDC, Northpond Ventures.
How much funding has Aro Biotherapeutics raised?: Aro Biotherapeutics has disclosed $164.4M raised across 5 of its 6 known rounds.
Where is Aro Biotherapeutics headquartered?: Aro Biotherapeutics is headquartered in Philadelphia, US.